Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients-Reference-Cited by-同舟云学术

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients

Published:2016-08-11 Issue:1 Volume:9 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Zhang Pin,Tong Zhongsheng,Tian Fuguo,Wang Yongsheng,Yang Junlan,Li Weilian,Di Lijun,Liu Wei,Tang Li,Qiu Rongguo,Xu Binghe

Funder

Beijing Biostar Tech, Ltd, Beijing, China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-016-0297-7

Reference20 articles.

1. Bollag DM, McQueney PA, Zhu J. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55(11):2325–33.

2. Giannakakou P, Gussio R, Nogales E. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A. 2000;97(6):2904–9.

3. Fumoleau P, Coudert B, Isambert N. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18 Suppl 5:9–15.

4. Thomas ES, Gomez HL, Li RK. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–7.

5. Bristol-Myers Squibb: Ixempra® Prescribing Information. 3/2009 update. www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf (date last Accessed: 1 June 2016)

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of utidelone and capecitabine versus monotherapy in anthracycline- and taxane-refractory metastatic breast cancer;Frontiers in Pharmacology;2024-07-11

2. Dihydromyricetin reverses capecitabine‐induced peripheral myelin dysfunction through modulation of oxidative stress;Clinical and Experimental Pharmacology and Physiology;2024-01-09

3. Research Progress of Ebomycin Antitumor Drugs in Breast Cancer;Hans Journal of Medicinal Chemistry;2024

4. Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study;Surgery Open Science;2023-12

5. Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801);Cancer Pathogenesis and Therapy;2023-10